CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.

HC Wainwright & Co. has decided to maintain its Buy rating of CASI Pharmaceuticals (NASDAQ:CASI) and raise its price target from $10.00 to $12.00. Shares of CASI Pharmaceuticals are trading up 1.33% over the last 24 hours, at $4.56 per share. A move to $12.00 would account for a 163.16% increase from the current share price. About CASI Pharmaceut...

USANA Health (USNA) delivered earnings and revenue surprises of -7.81% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced it plans to report new and updated data from the global randomized combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release on Oct. 11. Wheeler Real Estate Investment Trust, ...

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 36.17% and 37.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?